Mydecine Innovations Group Provides Corporate Update
VANCOUVER, British Columbia, July 21, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company…
Browsing Tag
Aequitas Neo Exchange:MYCO.NE
Mydecine Reports its Special Meeting Results
VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company…
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its…
<!-- Name:DistributionId Value:8824006 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap…
DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave…
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under…
DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave…
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the…
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting…
DENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform…
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment…
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
DENVER, March 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform…
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
DENVER, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform…